已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group

医学 长春瑞滨 内科学 化疗 长春花 危险系数 依托泊苷 顺铂 肺癌 长春花生物碱 阶段(地层学) 肿瘤科 长春碱 临床试验 置信区间 药理学 环磷酰胺 长春新碱 古生物学 生物
作者
Jean‐Pierre Pignon,Hélène Tribodet,Giorgio V. Scagliotti,Jean-Yves Douillard,Frances A. Shepherd,Richard Stephens,Ariane Dunant,Valter Torri,Rafael Rosell,Lesley Seymour,Stephen Spiro,Estelle Rolland,Roldano Fossati,D. Aubert,Keyue Ding,David Waller,Thierry Le Chevalier
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:26 (21): 3552-3559 被引量:2407
标识
DOI:10.1200/jco.2007.13.9030
摘要

Several recent trials have shown a significant overall survival (OS) benefit from postoperative cisplatin-based chemotherapy in patients with non-small-cell lung cancer (NSCLC). The aim of the Lung Adjuvant Cisplatin Evaluation was to identify treatment options associated with a higher benefit or groups of patients who particularly benefit from postoperative chemotherapy.Individual patient data were collected and pooled from the five largest trials (4,584 patients) of cisplatin-based chemotherapy in completely resected patients that were conducted after the 1995 NSCLC meta-analysis. The interactions between patient subgroups or treatment types and chemotherapy effect on OS were analyzed using hazard ratios (HRs) and log-rank tests stratified by trial.With a median follow-up time of 5.2 years, the overall HR of death was 0.89 (95% CI, 0.82 to 0.96; P = .005), corresponding to a 5-year absolute benefit of 5.4% from chemotherapy. There was no heterogeneity of chemotherapy effect among trials. The benefit varied with stage (test for trend, P = .04; HR for stage IA = 1.40; 95% CI, 0.95 to 2.06; HR for stage IB = 0.93; 95% CI, 0.78 to 1.10; HR for stage II = 0.83; 95% CI, 0.73 to 0.95; and HR for stage III = 0.83; 95% CI, 0.72 to 0.94). The effect of chemotherapy did not vary significantly (test for interaction, P = .11) with the associated drugs, including vinorelbine (HR = 0.80; 95% CI, 0.70 to 0.91), etoposide or vinca alkaloid (HR = 0.92; 95% CI, 0.80 to 1.07), or other (HR = 0.97; 95% CI, 0.84 to 1.13). Chemotherapy effect was higher in patients with better performance status. There was no interaction between chemotherapy effect and sex, age, histology, type of surgery, planned radiotherapy, or planned total dose of cisplatin.Postoperative cisplatin-based chemotherapy significantly improves survival in patients with NSCLC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
xrq发布了新的文献求助10
1秒前
直率的心情完成签到,获得积分10
1秒前
Hello应助如意的冰双采纳,获得10
2秒前
ylc发布了新的文献求助10
2秒前
luwenxuan完成签到,获得积分10
3秒前
天空发布了新的文献求助10
3秒前
3秒前
唐浩发布了新的文献求助10
3秒前
Mr.Young完成签到,获得积分10
3秒前
陶醉的又夏完成签到 ,获得积分10
4秒前
5秒前
5秒前
5秒前
摩卡桃桃冰完成签到,获得积分10
7秒前
7秒前
量子星尘发布了新的文献求助10
8秒前
元气少女猪刚鬣应助alpaca5采纳,获得10
10秒前
Lynny完成签到 ,获得积分10
11秒前
zyj完成签到,获得积分10
11秒前
几两完成签到 ,获得积分10
11秒前
12秒前
12秒前
13秒前
唐浩完成签到,获得积分10
14秒前
lsx完成签到,获得积分10
15秒前
xycrise发布了新的文献求助10
16秒前
小李关注了科研通微信公众号
16秒前
kdjm688发布了新的文献求助10
16秒前
微兔小妹完成签到 ,获得积分10
17秒前
17秒前
天空完成签到,获得积分10
17秒前
17秒前
yy湫完成签到,获得积分10
17秒前
小贾爱喝冰美式完成签到 ,获得积分10
18秒前
明亮的遥完成签到 ,获得积分0
18秒前
幸符完成签到 ,获得积分10
18秒前
jianguo完成签到,获得积分10
19秒前
azhou176完成签到,获得积分10
21秒前
络绎发布了新的文献求助10
21秒前
Vincey完成签到,获得积分10
21秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Social Research Methods (4th Edition) by Maggie Walter (2019) 2390
A new approach to the extrapolation of accelerated life test data 1000
北师大毕业论文 基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 390
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Robot-supported joining of reinforcement textiles with one-sided sewing heads 360
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4007513
求助须知:如何正确求助?哪些是违规求助? 3547373
关于积分的说明 11298234
捐赠科研通 3282661
什么是DOI,文献DOI怎么找? 1810162
邀请新用户注册赠送积分活动 885950
科研通“疑难数据库(出版商)”最低求助积分说明 811138